INVO Bioscience (IVOB): Disrupting the Infertility Market

[Article via Equities Research] According to the Centers for Disease Control, about 12% of women in the US between the ages of 15 and 44 have difficulty conceiving. That's about 7.4 million women, based on 2010 census numbers, and worldwide estimates place the number of infertile women at 150 million. Approximately $3 billion is spent annually in the US on in-vitro fertilization (IVF) and intrauterine insemination (IUI) cycles, and Allied Market Research projects the global IVF market alone to exceed $21 billion by 2020.

The vast majority - 98% - of infertile patients go untreated, with cost and proximity to treatment centers as the greatest hindrance. We've been following a company called INVO Bioscience (OTC: IVOB) that has developed the first new device and treatment for infertility in more than 30 years that produces results comparable to IVF at half the cost.

Read the full article here.